These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 25583724)
1. Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998. Kelley WL; Jousselin A; Barras C; Lelong E; Renzoni A Antimicrob Agents Chemother; 2015 Apr; 59(4):1922-30. PubMed ID: 25583724 [TBL] [Abstract][Full Text] [Related]
2. Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013-2014 at the Geneva University Hospitals. Andrey DO; François P; Manzano C; Bonetti EJ; Harbarth S; Schrenzel J; Kelley WL; Renzoni A Eur J Clin Microbiol Infect Dis; 2017 Feb; 36(2):343-350. PubMed ID: 27744604 [TBL] [Abstract][Full Text] [Related]
3. Ceftaroline Resistance by Clone-Specific Polymorphism in Penicillin-Binding Protein 2a of Methicillin-Resistant Staphylococcus aureus. Lee H; Yoon EJ; Kim D; Kim JW; Lee KJ; Kim HS; Kim YR; Shin JH; Shin JH; Shin KS; Kim YA; Uh Y; Jeong SH Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941637 [TBL] [Abstract][Full Text] [Related]
4. Missense mutations of PBP2a are associated with reduced susceptibility to ceftaroline and ceftobiprole in African MRSA. Schaumburg F; Peters G; Alabi A; Becker K; Idelevich EA J Antimicrob Chemother; 2016 Jan; 71(1):41-4. PubMed ID: 26443816 [TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline. Lahiri SD; McLaughlin RE; Whiteaker JD; Ambler JE; Alm RA J Antimicrob Chemother; 2015 Sep; 70(9):2488-98. PubMed ID: 26045529 [TBL] [Abstract][Full Text] [Related]
6. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. Mendes RE; Tsakris A; Sader HS; Jones RN; Biek D; McGhee P; Appelbaum PC; Kosowska-Shick K J Antimicrob Chemother; 2012 Jun; 67(6):1321-4. PubMed ID: 22398650 [TBL] [Abstract][Full Text] [Related]
7. In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program. Biedenbach DJ; Alm RA; Lahiri SD; Reiszner E; Hoban DJ; Sahm DF; Bouchillon SK; Ambler JE Antimicrob Agents Chemother; 2016 Jan; 60(1):343-7. PubMed ID: 26503659 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus Isolates. Sader HS; Rhomberg PR; Doyle TB; Flamm RK; Mendes RE J Clin Microbiol; 2018 Dec; 56(12):. PubMed ID: 30257898 [TBL] [Abstract][Full Text] [Related]
9. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. Alm RA; McLaughlin RE; Kos VN; Sader HS; Iaconis JP; Lahiri SD J Antimicrob Chemother; 2014 Aug; 69(8):2065-75. PubMed ID: 24777906 [TBL] [Abstract][Full Text] [Related]
10. Genotypic analysis of Italian MRSA strains exhibiting low-level ceftaroline and ceftobiprole resistance. Bongiorno D; Mongelli G; Stefani S; Campanile F Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114852. PubMed ID: 31288948 [TBL] [Abstract][Full Text] [Related]
15. Identification of non-PBP2a resistance mechanisms in Staphylococcus aureus after serial passage with ceftaroline: involvement of other PBPs. Lahiri SD; Alm RA J Antimicrob Chemother; 2016 Nov; 71(11):3050-3057. PubMed ID: 27494915 [TBL] [Abstract][Full Text] [Related]
16. Prevalence and molecular epidemiology of ceftaroline non-susceptible methicillin-resistant Staphylococcus aureus isolates, first clinical report from Iran. Khoshbayan A; Shariati A; Ghaznavi-Rad E; van Belkum A; Darban-Sarokhalil D Acta Microbiol Immunol Hung; 2020 Dec; 67(4):228-233. PubMed ID: 33258796 [TBL] [Abstract][Full Text] [Related]
17. Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. Castanheira M; Sader HS; Farrell DJ; Mendes RE; Jones RN Antimicrob Agents Chemother; 2012 Sep; 56(9):4779-85. PubMed ID: 22733066 [TBL] [Abstract][Full Text] [Related]
18. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program. Sader HS; Flamm RK; Farrell DJ; Jones RN Clin Infect Dis; 2012 Sep; 55 Suppl 3():S181-6. PubMed ID: 22903950 [TBL] [Abstract][Full Text] [Related]
19. Impact of EUCAST ceftaroline breakpoint change on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from patients with complicated skin and soft-tissue infections. Urbán E; Stone GG Clin Microbiol Infect; 2019 Nov; 25(11):1429.e1-1429.e4. PubMed ID: 30980925 [TBL] [Abstract][Full Text] [Related]
20. In vitro activity of ceftaroline against methicillin-resistant and methicillin-susceptible Staphylococcus aureus clinical isolates from a tertiary hospital in Greece. Tychala A; Protonotariou E; Meletis G; Tsoha A; Mantzana P; Vasilaki O; Kagkalou G; Skoura L New Microbiol; 2021 Apr; 44(2):125-128. PubMed ID: 34151995 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]